|
Cocrystal Pharma Inc (NASDAQ: COCP) |
|
Cocrystal Pharma Inc
COCP's Fundamental analysis
Select the Comparisons :
|
|
Select the Ratio:
|
|
|
Cocrystal Pharma Inc 's sales fell
in the fourth quarter of 2024 from the same quarter a year ago.
Major Pharmaceutical Preparations industry recorded
growth of revenues by 11.85 %
Cocrystal Pharma Inc net loss increased from $-3 millions, to $-3 millions in fourth quarter of 2024,
• More on COCP's Growth
|
|
Cocrystal Pharma Inc realized a net loss in trailing twelve months.
Cocrystal Pharma Inc realized cash reduction of $ -1.62 per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.29.
• More on COCP's Valuation
|
|
|
|
|
Cocrystal Pharma Inc realized net loss in trailing twelve months.
Cocrystal Pharma Inc realized cash outflow of $ -1.62per share in trailing twelve-month period. |
Company |
- |
PE TTM
|
Industry |
- |
PE TTM
|
|
Major Pharmaceutical Preparations industry's Price to Sales ratio is at 5.29.
Cocrystal Pharma Inc Price to Book Ratio is at 1.66 lower than Industry Avg. of 33.9. and higher than S&P 500 Avg. of 0.01
• More on COCP's Valuation
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com